Over the last few decades, genetic research has opened doors to improve the treatment of immune-mediated conditions like psoriasis, but there are still questions about how these diseases are triggered at the cellular level.
Highly effective medications for severe disease are expensive and administered invasively, while the development of treatments for milder disease has lagged, a new review on psoriasis clinical trials concludes.